Sio Gene Therapies, Inc. (NASDAQ:SIOX) Expected to Announce Earnings of -$0.19 Per Share
Wall Street brokerages expect that Sio Gene Therapies, Inc. (NASDAQ:SIOX) will report earnings of ($0.19) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Sio Gene Therapies’ earnings. The highest EPS estimate is ($0.02) and the lowest is ($0.35). Sio Gene Therapies posted earnings per share of ($0.54) during the same quarter last year, which would suggest a positive year over year growth rate of 64.8%. The company is expected to issue its next quarterly earnings report on Wednesday, June 9th.
According to Zacks, analysts expect that Sio Gene Therapies will report full-year earnings of ($0.78) per share for the current fiscal year, with EPS estimates ranging from ($0.98) to ($0.61). For the next year, analysts expect that the firm will post earnings of ($0.92) per share, with EPS estimates ranging from ($1.16) to ($0.77). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Sio Gene Therapies.
Sio Gene Therapies (NASDAQ:SIOX) last announced its earnings results on Monday, February 8th. The company reported ($0.20) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.09.
Shares of SIOX traded down $0.13 during mid-day trading on Tuesday, hitting $2.91. 55,223 shares of the company traded hands, compared to its average volume of 1,725,592. The stock has a market capitalization of $137.50 million and a price-to-earnings ratio of -1.54. The business has a 50-day moving average of $2.97 and a 200 day moving average of $3.07. Sio Gene Therapies has a one year low of $1.41 and a one year high of $5.74.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new position in Sio Gene Therapies during the fourth quarter worth about $32,000. Lindbrook Capital LLC bought a new stake in Sio Gene Therapies during the 3rd quarter worth approximately $60,000. ExodusPoint Capital Management LP acquired a new stake in Sio Gene Therapies during the 4th quarter worth approximately $88,000. Prelude Capital Management LLC bought a new position in Sio Gene Therapies in the fourth quarter valued at approximately $95,000. Finally, Wells Fargo & Company MN bought a new stake in shares of Sio Gene Therapies during the fourth quarter worth $100,000. Institutional investors and hedge funds own 24.12% of the company’s stock.
About Sio Gene Therapies
Sio Gene Therapies, Inc, a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis.
See Also: Pattern Day Trader
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sio Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.